Targeting prolyl-tRNA synthetase via a series of ATP-mimetics to accelerate drug discovery against toxoplasmosis.
The prolyl-tRNA synthetase (PRS) is a validated drug target for febrifugine and its synthetic analog halofuginone (HFG) against multiple apicomplexan parasites including Plasmodium falciparum and Toxoplasma gondii. Here, a novel ATP-mimetic centered on 1-(pyridin-4-yl) pyrrolidin-2-one (PPL) scaffol...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2023-02-01
|
| Series: | PLoS Pathogens |
| Online Access: | https://doi.org/10.1371/journal.ppat.1011124 |
| _version_ | 1797848210172018688 |
|---|---|
| author | Manickam Yogavel Alexandre Bougdour Siddhartha Mishra Nipun Malhotra Jyoti Chhibber-Goel Valeria Bellini Karl Harlos Benoît Laleu Mohamed-Ali Hakimi Amit Sharma |
| author_facet | Manickam Yogavel Alexandre Bougdour Siddhartha Mishra Nipun Malhotra Jyoti Chhibber-Goel Valeria Bellini Karl Harlos Benoît Laleu Mohamed-Ali Hakimi Amit Sharma |
| author_sort | Manickam Yogavel |
| collection | DOAJ |
| description | The prolyl-tRNA synthetase (PRS) is a validated drug target for febrifugine and its synthetic analog halofuginone (HFG) against multiple apicomplexan parasites including Plasmodium falciparum and Toxoplasma gondii. Here, a novel ATP-mimetic centered on 1-(pyridin-4-yl) pyrrolidin-2-one (PPL) scaffold has been validated to bind to Toxoplasma gondii PRS and kill toxoplasma parasites. PPL series exhibited potent inhibition at the cellular (T. gondii parasites) and enzymatic (TgPRS) levels compared to the human counterparts. Cell-based chemical mutagenesis was employed to determine the mechanism of action via a forward genetic screen. Tg-resistant parasites were analyzed with wild-type strain by RNA-seq to identify mutations in the coding sequence conferring drug resistance by computational analysis of variants. DNA sequencing established two mutations, T477A and T592S, proximal to terminals of the PPL scaffold and not directly in the ATP, tRNA, or L-pro sites, as supported by the structural data from high-resolution crystal structures of drug-bound enzyme complexes. These data provide an avenue for structure-based activity enhancement of this chemical series as anti-infectives. |
| first_indexed | 2024-04-09T18:23:46Z |
| format | Article |
| id | doaj.art-e8c18ac0c4d34cadb55ade27bc2b2c94 |
| institution | Directory Open Access Journal |
| issn | 1553-7366 1553-7374 |
| language | English |
| last_indexed | 2024-04-09T18:23:46Z |
| publishDate | 2023-02-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS Pathogens |
| spelling | doaj.art-e8c18ac0c4d34cadb55ade27bc2b2c942023-04-12T05:31:31ZengPublic Library of Science (PLoS)PLoS Pathogens1553-73661553-73742023-02-01192e101112410.1371/journal.ppat.1011124Targeting prolyl-tRNA synthetase via a series of ATP-mimetics to accelerate drug discovery against toxoplasmosis.Manickam YogavelAlexandre BougdourSiddhartha MishraNipun MalhotraJyoti Chhibber-GoelValeria BelliniKarl HarlosBenoît LaleuMohamed-Ali HakimiAmit SharmaThe prolyl-tRNA synthetase (PRS) is a validated drug target for febrifugine and its synthetic analog halofuginone (HFG) against multiple apicomplexan parasites including Plasmodium falciparum and Toxoplasma gondii. Here, a novel ATP-mimetic centered on 1-(pyridin-4-yl) pyrrolidin-2-one (PPL) scaffold has been validated to bind to Toxoplasma gondii PRS and kill toxoplasma parasites. PPL series exhibited potent inhibition at the cellular (T. gondii parasites) and enzymatic (TgPRS) levels compared to the human counterparts. Cell-based chemical mutagenesis was employed to determine the mechanism of action via a forward genetic screen. Tg-resistant parasites were analyzed with wild-type strain by RNA-seq to identify mutations in the coding sequence conferring drug resistance by computational analysis of variants. DNA sequencing established two mutations, T477A and T592S, proximal to terminals of the PPL scaffold and not directly in the ATP, tRNA, or L-pro sites, as supported by the structural data from high-resolution crystal structures of drug-bound enzyme complexes. These data provide an avenue for structure-based activity enhancement of this chemical series as anti-infectives.https://doi.org/10.1371/journal.ppat.1011124 |
| spellingShingle | Manickam Yogavel Alexandre Bougdour Siddhartha Mishra Nipun Malhotra Jyoti Chhibber-Goel Valeria Bellini Karl Harlos Benoît Laleu Mohamed-Ali Hakimi Amit Sharma Targeting prolyl-tRNA synthetase via a series of ATP-mimetics to accelerate drug discovery against toxoplasmosis. PLoS Pathogens |
| title | Targeting prolyl-tRNA synthetase via a series of ATP-mimetics to accelerate drug discovery against toxoplasmosis. |
| title_full | Targeting prolyl-tRNA synthetase via a series of ATP-mimetics to accelerate drug discovery against toxoplasmosis. |
| title_fullStr | Targeting prolyl-tRNA synthetase via a series of ATP-mimetics to accelerate drug discovery against toxoplasmosis. |
| title_full_unstemmed | Targeting prolyl-tRNA synthetase via a series of ATP-mimetics to accelerate drug discovery against toxoplasmosis. |
| title_short | Targeting prolyl-tRNA synthetase via a series of ATP-mimetics to accelerate drug discovery against toxoplasmosis. |
| title_sort | targeting prolyl trna synthetase via a series of atp mimetics to accelerate drug discovery against toxoplasmosis |
| url | https://doi.org/10.1371/journal.ppat.1011124 |
| work_keys_str_mv | AT manickamyogavel targetingprolyltrnasynthetaseviaaseriesofatpmimeticstoacceleratedrugdiscoveryagainsttoxoplasmosis AT alexandrebougdour targetingprolyltrnasynthetaseviaaseriesofatpmimeticstoacceleratedrugdiscoveryagainsttoxoplasmosis AT siddharthamishra targetingprolyltrnasynthetaseviaaseriesofatpmimeticstoacceleratedrugdiscoveryagainsttoxoplasmosis AT nipunmalhotra targetingprolyltrnasynthetaseviaaseriesofatpmimeticstoacceleratedrugdiscoveryagainsttoxoplasmosis AT jyotichhibbergoel targetingprolyltrnasynthetaseviaaseriesofatpmimeticstoacceleratedrugdiscoveryagainsttoxoplasmosis AT valeriabellini targetingprolyltrnasynthetaseviaaseriesofatpmimeticstoacceleratedrugdiscoveryagainsttoxoplasmosis AT karlharlos targetingprolyltrnasynthetaseviaaseriesofatpmimeticstoacceleratedrugdiscoveryagainsttoxoplasmosis AT benoitlaleu targetingprolyltrnasynthetaseviaaseriesofatpmimeticstoacceleratedrugdiscoveryagainsttoxoplasmosis AT mohamedalihakimi targetingprolyltrnasynthetaseviaaseriesofatpmimeticstoacceleratedrugdiscoveryagainsttoxoplasmosis AT amitsharma targetingprolyltrnasynthetaseviaaseriesofatpmimeticstoacceleratedrugdiscoveryagainsttoxoplasmosis |